A Phase 1b, Open-label, Safety And Tolerability Study Of Oral Mdv3100 In Combination With Docetaxel In Men With Advanced Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Medivation; Pfizer
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 29 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.